

ABSTRACT

The present invention relates to therapeutic associations for the treatment of cancer, comprising an effective amount of a camptothecin, or a camptothecin derivative, with an effective amount of a topoisomerase II inhibitor, such as doxorubicin, daunorubicin, or etoposide, and methods of using such therapeutic associations.